紫杉醇联合顺铂治疗晚期食管癌的疗效及安全性评价

Therapeutic effects and safety evaluation of cisplatin combined with paclitaxel on treatment of advanced esophageal cancer

目的探讨紫杉醇联合顺铂治疗晚期食管癌的临床疗效及安全性。方法将62例晚期食管癌患者随机分为观察组和对照组,每组31例。观察组患者采用紫杉醇联合顺铂化疗方案治疗,对照组采用顺铂联合氟尿嘧啶方案治疗。结果观察组和对照组的有效率分别为67.7%和51.6%,病情控制率分别为93.5%和80.6%,观察组有效率及疾病控制率均显著高于对照组,差异均具有统计学意义(P<0.05);观察组骨髓抑制、消化道反应及变态反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论紫杉醇联合顺铂治疗晚期食管癌临床疗效确切,且不良反应小,安全可靠。

Objective To investigate the therapeutic effects and evaluate the safety of cisplatin combined with paclitaxel on advanced esophageal cancer. Methods Sixty-two patients with advanced esophageal cancer were collected and randomly divided into observation group and control group, with 31 patients in each group. Patients in the observation group were treated with cisplatin combined with paclitaxel chemotherapy, while patients in the control group were treated with cisplatin in combination with fluorouracil. Results The effective rate and disease control rate of observation group were 67.7% and 93.5% individually, which were significantly higher than that of control group （P 0.05）; The incidence of adverse effects such as myelosuppression, gastrointestinal reaction and allergic reactions of observation group were lower than that of control group with statistical significance （P 0.05）. Conclusion The treatment of cisplatin combined with paclitaxel is effective on the therapy of advanced esophageal cancer with low incidence rate of adverse effects, which is an safe and efficient program for treatment of advanced esophageal cancer.